Catinazzo Thomas, the Chief Financial Officer of Relay Therapeutics, Inc., has reported the sale of shares in the company, a move that underscores ongoing financial strategies within the biotechnology sector.
According to the recent SEC filing dated October 8, 2026, Catinazzo sold a total of 17,511 shares at a weighted average price of $18.58, as well as an additional 206 shares at a weighted average price of $19.26. These transactions were executed on October 6, 2026, and were part of a Rule 10b5-1 trading plan adopted by Catinazzo on October 30, 2025.
Background
Relay Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies in the life sciences sector. The company operates under the SIC classification for biological products, specifically those that do not include diagnostic substances. Relay Therapeutics is based in Cambridge, Massachusetts, and is publicly traded under the ticker symbol RLAY.
What the Filing Says
The filing indicates that Catinazzo's sales were executed in multiple trades, reflecting a structured approach to managing his equity in the company. The filing notes, "The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025." Following these transactions, Catinazzo retains ownership of 105,340 shares, which includes 6,538 shares underlying restricted stock units.
Impact
This transaction may affect Relay Therapeutics' market perception, as executive share sales can sometimes raise questions among investors regarding the company's future prospects. However, the structured nature of the sales under a trading plan may mitigate concerns about insider trading.
What's Next
The filing does not say what happens next.